Clinical Trials | June 16, 2026
Lilly’s Jaypirca cuts risk of disease progression or death by 45% in landmark trial
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
Study introduces structured, condition-specific emergency coding system to improve coordination, response time, and patient safety in tertiary care hospitals
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The event also featured discussions on emerging trends in joint replacement surgery
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
